SBB,
Gene editing,
Automation,
DNA,
Event,
Laboratory,
Apple IIe,
Growth,
Genome,
High fidelity,
Investment,
Conference,
Genetics,
PARK,
Video game,
Pharmaceutical industry,
Sequel,
Abraxis BioScience MENLO PARK, Calif., Jan. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today it received orders for 76 Revio systems in its fourth quarter ended December 31, 2022, making it the most successful product announcement in PacBio's history.
Key Points:
- PacBio commenced its beta program for Onso in the fourth quarter of 2022.
- PacBio expects to begin taking orders this quarter and start shipping by the end of the second quarter of 2023.
- Received orders for 96 instruments in the fourth quarter, which included orders for 76 Revio systems for delivery in 2023.
- Placed 18 Sequel II/IIe systems during the fourth quarter compared to 48 Sequel II/IIe systems placed in the prior year quarter.
"Through this collaboration with the University of Tokyo, we plan on developing and applying new methods in the hopes of identifying genetic mutations of many diseases impacting the Japanese population," said Michael Eberle, Vice President of Computational Biology at PacBio.
Key Points:
- "Through this collaboration with the University of Tokyo, we plan on developing and applying new methods in the hopes of identifying genetic mutations of many diseases impacting the Japanese population," said Michael Eberle, Vice President of Computational Biology at PacBio.
- "This will help improve our understanding of difficult genetic regions and variants that we hope will benefit the Japanese population."
- "Collaborating with PacBio in applying advanced bioinformatics workflows should accelerate our in-progress work characterizing structural variants and making these findings more accessible to the broader scientific community.
- We believe this collaboration will complement our previous work and help us identify many more disease-causing structural variations in the human genome," said Dr. Shoji Tsuji, a senior investigator for the University of Tokyo Hospital, Department of Neurology.
MENLO PARK, Calif., Dec. 28, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following events at the 41st Annual J.P. Morgan Healthcare Conference:
Key Points:
- MENLO PARK, Calif., Dec. 28, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following events at the 41st Annual J.P. Morgan Healthcare Conference:
Panel | Multiomics: Markers for Modern Medicine on Tuesday, January 10, 2023, at approximately 5:15 PM PT.
- Company presentation and Q&A session on Wednesday, January 11, 2023, at approximately 1:30 PM PT.
- The live webcasts of the events can be accessed at the company's investors page at investor.pacificbiosciences.com.
- For more information, please visit www.pacb.com and follow @PacBio.
SBB,
Genome,
Security (finance),
Boston Children's Hospital,
Infection,
High fidelity,
Research,
Leukemia,
Patient,
DNA,
DNA methylation,
Degenerative disease,
Microbiology,
Epilepsy,
Genomics,
Hospital,
Pacific Biosciences,
Congenital hearing loss,
Pharmaceutical industry,
Medical imaging,
Abraxis BioScience MENLO PARK, Calif., Dec. 6, 2022 /PRNewswire/ -- PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced its HiFi sequencing technology will be used in a pilot project for the Children's Rare Disease Cohorts Initiative (CRDC) at Boston Children's Hospital. Boston Children's Hospital researchers will use HiFi whole-genome sequencing (HiFi WGS) for the purpose of investigating genetic and epigenetic variants associated with rare pediatric diseases. Samples from individuals enrolled in multiple rare disease cohorts that have remained undiagnosed after short-read whole exome sequencing will be examined using HiFi WGS. The study will also explore epigenetic variation using the ability of HiFi WGS to measure DNA methylation in every sequencing run.
Key Points:
- Boston Children's Hospital researchers will use HiFi whole-genome sequencing (HiFi WGS) for the purpose of investigating genetic and epigenetic variants associated with rare pediatric diseases.
- The study will also explore epigenetic variation using the ability of HiFi WGS to measure DNA methylation in every sequencing run.
- In previous research conducted using PacBio's technology, HiFi sequencing detected more than two-fold structural variants and 200,000 more single-nucleotide variants than short-read sequencing.
- "HiFi sequencing holds the promise to investigate parts of the genome inaccessible via other technologies," said Piotr Sliz, Vice President and Chief Research Information Officer at Boston Children's Hospital.
Financial Services Forum,
Digital health,
Pacific Biosciences,
NASDAQ,
SBB,
Microbiology,
Technology,
Research,
Solution,
Diagnosis,
Conference,
Infection,
High fidelity A webcast replay will be available for at least 30 days following the presentation.
Key Points:
- A webcast replay will be available for at least 30 days following the presentation.
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.
- Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.
- For more information, please visit www.pacb.com and follow @PacBio.
MENLO PARK, Calif., Nov. 2, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced it is bringing together a group of scientific experts to form PacBio's Scientific Advisory Board (SAB). The SAB will provide guidance to the research and development efforts at PacBio, including critical feedback, advice, and expertise on future technological and scientific direction to inform PacBio's priorities and roadmaps for current and future products. The goal of the SAB is to help provide a strong voice for the future of the 'omics and quantitative biology fields, while advocating for ways PacBio can create that future.
Key Points:
- SAB members were chosen based on their leadership in fields such as biophysics, genomics, medicine, biology, chemistry and/or chip fabrication.
- In 2010, he led the team that carried out the first clinical interpretation of a human genome.
- He was a recipient of the National Innovation Award from the American Heart Association and the NIH Director's New Innovator Award.
- "I am honored and delighted to join PacBio's scientific advisory board," said Jody Puglisi, Ph.D., Jauch Professor and Professor of Structural Biology at Stanford University.
U.S. Securities and Exchange Commission,
Infection,
Interest,
Microbiology,
Sequel,
Investor relations,
Deep learning,
Child,
Architecture,
Population,
DNA methylation,
Google Health,
Workflow,
NVIDIA,
Genomics,
NASDAQ,
ZMW attack,
PARK,
Cheung,
Research,
Corteva,
Security (finance),
Technology,
Private Securities Litigation Reform Act,
Apple IIe,
Marketing,
MD,
Doctor of Philosophy,
SMRT,
Securities Exchange Act of 1934,
Genetics,
Genome,
European,
DNA,
Pacific Biosciences,
Solution,
Computing,
Algorithm,
Antibiotics,
Fine chemical,
Medical imaging,
High fidelity,
Abraxis BioScience,
Biotechnology MENLO PARK, Calif., Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the Revio™ long-read sequencing system, which will enable customers to dramatically scale their use of PacBio's celebrated HiFi sequencing technology. Revio is designed to provide customers with the ability to sequence up to 1,300 human whole genomes per year at 30-fold coverage for less than $1,000 per genome. With this scale and pricing, PacBio believes Revio will enable the use of HiFi sequencing for large studies in human genetics, cancer research, agricultural genomics, and more.
Key Points:
- With this scale and pricing, PacBio believes Revio will enable the use of HiFi sequencing for large studies in human genetics, cancer research, agricultural genomics, and more.
- Revio will further unleash that power by adding high throughput and affordability," said Christian Henry, President and Chief Executive Officer of PacBio.
- Revio will run up to four SMRT Cells in parallel, which provides up to 100 million ZMWs for sequencing single molecules simultaneously.
- Combined with significant advances in our compute, Revio will deliver shorter run times and a 15-fold increase in HiFi data.
U.S. Securities and Exchange Commission,
Infection,
Interest,
High fidelity,
Microbiology,
Investor relations,
Efficiency,
Science,
Workflow,
Weill Cornell Medicine,
NASDAQ,
Gene editing,
Research,
Security (finance),
Technology,
Private Securities Litigation Reform Act,
Harvard University,
Marketing,
Broad Institute,
Ecosystem,
Securities Exchange Act of 1934,
MIT,
Corteva,
Genomics,
Recurrence,
SBB,
Genome,
Pacific Biosciences,
DNA,
Single-cell analysis,
Solution,
Book,
Online shopping,
Medical imaging,
Fine chemical,
Abraxis BioScience,
Biotechnology MENLO PARK, Calif., Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the commencement of external beta testing of the Onso™ sequencing system. This innovative benchtop short-read DNA sequencing platform is expected to provide an extraordinary level of accuracy by utilizing PacBio's unique sequencing by binding (SBB) technology.
Key Points:
- MENLO PARK, Calif., Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the commencement of external beta testing of the Onsosequencing system.
- This innovative benchtop short-read DNA sequencing platform is expected to provide an extraordinary level of accuracy by utilizing PacBio's unique sequencing by binding (SBB) technology.
- "We are excited to see how researchers will leverage the ground-breaking sequencing accuracy that we expect Onso to deliver.
- "Onso is designed to deliver highly accurate sequencing reads, support scalable, flexible, and cost-optimized operation, and enable customers to feel more confident in their science.
U.S. Securities and Exchange Commission,
Infection,
High fidelity,
Microbiology,
NASDAQ,
Research,
Security (finance),
Technology,
Private Securities Litigation Reform Act,
Q&A,
Securities Exchange Act of 1934,
SBB,
Pacific Biosciences,
Internet,
Solution,
Risk,
Broadcasting,
Medical imaging,
Abraxis BioScience MENLO PARK, Calif., Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2022 financial results on Monday, Nov. 7, 2022, at 5:00 p.m. Eastern Time.
Key Points:
- PacBio will also host its Inaugural Investor Day on Tuesday, Nov. 15, 2022, at 8:00 a.m. Eastern Time.
- The event will feature presentations by members of PacBio's executive team and include Q&A sessions.
- Both events will be webcast live and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/ .
- We plan to provide additional information during our third quarter earnings call on Nov. 7, 2022.
Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
Key Points:
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
- We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
